In the war against two of the world’s most pressing health challenges – obesity and type-2 diabetes – a major new offensive has been opened by the discovery of a new generation of weight-loss drugs.
Of these new pharmaceutical interventions Ozempic, the brand name of manufacturer Novo Nordisk’s semaglutide formulation, has attracted the most interest and attention, not only for its ability to stabilise blood-sugar levels, but for its substantial weight-loss benefits.
If you’re overweight, suffer from diabetes, or both, the impact of these new drugs is profound: they might just save your life.
But even if you’re as fit as a butcher’s dog you should still have a very keen interest in the pros and cons of these new medications.
Why? Treating obesity-related health issues costs $336 billion (£270bn) per year and accounts for a whopping 8.4% of total healthcare spending in OECD countries, accounting to the Organisation for Economic Co-operation and Development.
That’s an awful lot of money that could be otherwise invested in finding better treatments for other health problems that kill millions of people each year, including cardiovascular disease and cancer. Surely anything that can reduce the substantial economic impact of obesity on healthcare systems must be considered and explored.
To get you up to speed, here’s what you need to know about Ozempic and the other new-wave of weight-loss and obesity drugs, including how they work, who qualifies for them, and the both the short-term and long-term benefits and side effects of taking them.
What is Ozempic?
Ozempic, the brand name for Semaglutide, is a medication approved for the treatment of type-2 diabetes. Manufactured by Novo Nordisk, it belongs to a class of drugs known as GLP-1 receptor agonists. This medication is designed to help lower blood-sugar levels and has also been found to contribute significantly to weight loss.
It is administered via injection once per week, which makes it easy and convenient to administer compared to daily diabetes treatments. The claimed benefits of blood sugar regulation and weight loss make Ozempic an attractive option for people managing these interconnected health problems.
How does Ozempic work?
Ozempic operates by mimicking GLP-1 (glucagon-like peptide-1), a hormone that plays a key role in blood sugar regulation. Under normal circumstances, GLP-1 is released by the gut in response to food, triggering insulin production, suppressing glucagon (which raises blood sugar), and slowing digestion to promote satiety. By activating the GLP-1 receptor, Ozempic extends these effects—lowering blood glucose, delaying gastric emptying, and reducing appetite.
It’s this appetite-suppressing effect that has propelled Ozempic into the weight-loss spotlight, with some touting it as a revolution in obesity treatment. But while the drug helps regulate blood sugar and reduce calorie intake, the broader metabolic consequences of long-term GLP-1 manipulation remain uncertain. What happens when you override your body’s natural hunger signals? Could prolonged use of Ozempic alter gut-brain communication in ways we don’t yet understand? These are the questions that remain unanswered in the rush to prescribe the drug beyond its original remit.
Why am I hearing so much about Ozempic now?
Ozempic has exploded into public consciousness for one reason: weight loss. Originally developed to manage diabetes, the drug has demonstrated striking effects on body weight, leading to its approval—under the brand name Wegovy—as an obesity treatment. This dual positioning has made it a highly lucrative and highly controversial pharmaceutical product.
But its rise isn’t just about clinical effectiveness. A perfect storm of factors—the global obesity crisis, growing interest in medicalised weight management, and the social media-fuelled obsession with rapid transformation—has propelled Ozempic into the mainstream. High-profile users, from Hollywood celebrities to tech moguls, have only accelerated the hype, turning it into a status symbol as much as a medical intervention.
Yet, behind the glossy success stories, there are critical unanswered questions. What happens when people stop taking it? Are we trading one health crisis for another by encouraging long-term reliance on a drug that fundamentally alters metabolism? And with demand outstripping supply, who really gets access—those who need it most or those who can afford to jump the queue?
Is taking Ozempic the best way to lose body fat?
If the goal is sustainable fat loss and long-term health, the answer is almost certainly no.
Yes, Ozempic can reduce appetite and lead to weight loss, but at what cost? Unlike lifestyle interventions—such as resistance training, metabolic conditioning, and whole-food nutrition—which improve overall health, build muscle mass, and enhance metabolic flexibility, Ozempic artificially suppresses hunger without addressing the root causes of weight gain. It’s a shortcut, and like most shortcuts, it comes with risks.
Emerging research suggests that many people who stop taking Ozempic quickly regain lost weight, sometimes even surpassing their starting point. Why? Because they never built the habits, metabolic adaptations, and behavioural resilience that drive lasting change. Instead of improving metabolic function, Ozempic hijacks it, leading to questions about muscle loss, long-term hormonal impact, and dependency.
There’s also the reality that weight loss and fat loss are not the same thing. A reduction on the scale driven by reduced appetite can mean muscle loss as well as fat loss, potentially leaving people weaker, more insulin-resistant, and metabolically worse off in the long run.
Simply put: Ozempic is not a substitute for building a body that thrives. It may serve as a short-term aid for specific cases—particularly those with type-2 diabetes—but for anyone serious about long-term health and resilience, the real answer still lies in strength training, movement, quality nutrition, and sleep.
How do I qualify for Ozempic?
The eligibility criteria for prescribing weight-loss drugs including Ozempic typically include having a diagnosis of type-2 diabetes with a need for better glycemic control, or being diagnosed with obesity.
For obesity treatment, specifically under the brand name Wegovy, adults with a body mass index (BMI) of 30 or higher (obese) or 27 or higher (overweight) with at least one weight-related condition such as high blood pressure, type-2 diabetes, or high cholesterol may be candidates. Each case is assessed individually, considering overall health, potential benefits, and possible risks.
What are the side effects of Ozempic?
The short-term side effects of Ozempic are unpleasant but predictable: nausea, vomiting, diarrhoea, constipation, and abdominal pain—a cocktail of gastrointestinal distress that many users experience as their bodies adjust to the drug.
But the bigger concern is what happens with long-term use. Ozempic, like other GLP-1 receptor agonists, disrupts normal metabolic processes, and the consequences of this disruption are still unfolding. Studies have linked prolonged use of these drugs to pancreatitis, kidney issues, and severe gastrointestinal complications. There are also concerns about muscle loss, bone density reduction, and altered gut-brain signalling.
And then there’s the rebound effect. Once users stop taking Ozempic, many report rapid weight regain, sometimes exceeding their original weight. Why? Because the drug never taught their bodies how to manage hunger and energy balance—it simply turned off appetite like a switch. When that switch flips back on, the body compensates.
Is Ozempic a long-term weight-management solution?
The data suggests Ozempic can help sustain weight loss over time, but whether it’s a viable long-term solution is far less certain.
Clinical trials show that people who stay on GLP-1 receptor agonists like Ozempic can maintain significant weight loss for up to two years. But what happens beyond that? And more importantly, what happens when they stop taking it? Evidence indicates that many users regain weight rapidly, highlighting a fundamental issue: Ozempic suppresses appetite but doesn’t change underlying behaviours, metabolism, or body composition in a meaningful way.
For some, especially those with severe obesity or type-2 diabetes, Ozempic may serve as an important long-term tool. But it’s not a free pass to avoid the fundamentals of weight management—muscle-preserving resistance training, metabolic conditioning, and a nutrient-dense diet. In fact, using the drug without a structured exercise and nutrition plan may actually lead to muscle loss, metabolic slowdown, and long-term dependency.
Ultimately, Ozempic is not a magic bullet, nor is it a guaranteed long-term fix. It works best when integrated into a broader health strategy, not as a replacement for one. For anyone considering it, the real question is: what’s the exit plan? If stopping the drug means regaining weight, then is it really a sustainable solution—or just an expensive pause button?
Are there other drugs similar to Ozempic?
Yes, there are other drugs in the GLP-1 receptor agonist family similar to Ozempic, which work by enhancing insulin secretion, suppressing appetite, and slowing gastric emptying. Each has its unique dosing schedule, efficacy profile and side effects, but all share the common goal of improving blood-sugar levels and supporting weight-loss efforts.
Wegovy
Both Wegovy and Ozempic are based on semaglutide and manufactured by Novo Nordisk. While Ozempic is primarily used to treat type-2 diabetes, Wegovy is specifically dosed and approved for weight loss in adults with obesity or overweight status who have at least one weight-related condition such as hypertension, type-2 diabetes, or high cholesterol. The mechanism of action in Wegovy is the same as in Ozempic, mimicking an incretin hormone that stimulates insulin release, suppresses glucagon secretion, and delays gastric emptying to induce satiety and reduce appetite.
Victoza
Victoza, which contains liraglutide, is also a GLP-1 receptor agonist, but it is used primarily for diabetes management. Like Ozempic, Victoza enhances insulin secretion, suppresses glucagon production, and promotes satiety, but it is typically taken daily rather than weekly.
Trulicity
Trulicity, which contains dulaglutide, is another GLP-1 receptor agonist used to treat type-2 diabetes. Its effects are similar to those of semaglutide and liraglutide, including enhancing insulin release in response to meals, and slowing food leaving your stomach to help prevent blood-sugar spikes.
Byetta
Byetta, another GLP-1 receptor agonist, was originally derived from the saliva of the Gila monster, a species of venomous lizard native to the southwestern United States and northwestern Mexico. It stimulates insulin release in a glucose-dependent manner and has been shown to reduce hemoglobin A1C levels effectively.
